Envestnet Portfolio Solutions Inc. Boosts Holdings in IDEXX Laboratories, Inc. $IDXX

Envestnet Portfolio Solutions Inc. increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 45.4% in the fourth quarter, HoldingsChannel reports. The firm owned 30,675 shares of the company’s stock after buying an additional 9,580 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in IDEXX Laboratories were worth $20,753,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Gabelli Funds LLC grew its position in shares of IDEXX Laboratories by 44.2% in the fourth quarter. Gabelli Funds LLC now owns 685 shares of the company’s stock valued at $463,000 after purchasing an additional 210 shares during the period. Sapient Capital LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth approximately $265,000. North Dakota State Investment Board purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $2,097,000. Elyxium Wealth LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $3,666,459,000. Finally, iA Global Asset Management Inc. increased its stake in IDEXX Laboratories by 2.0% during the 4th quarter. iA Global Asset Management Inc. now owns 15,051 shares of the company’s stock worth $10,182,000 after buying an additional 299 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. BTIG Research lowered their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus cut their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Up 0.1%

IDEXX Laboratories stock opened at $546.49 on Wednesday. The company’s fifty day moving average price is $569.38 and its two-hundred day moving average price is $644.35. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a one year low of $496.61 and a one year high of $769.98. The company has a market capitalization of $43.11 billion, a price-to-earnings ratio of 40.24, a PEG ratio of 3.17 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the business earned $2.91 EPS. The business’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 2,693 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the sale, the executive vice president directly owned 19,899 shares in the company, valued at $13,163,984.46. This represents a 11.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the sale, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 27,777 shares of company stock valued at $18,235,113 over the last ninety days. 0.79% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.